Pacific Bio (NASDAQ: PACB) reported Q2 EPS of ($0.26), $0.06 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $47.57 million versus the consensus estimate of $40.2 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.